| Ticker | VTGN |
|---|---|
| ISIN | US92840H4002 |
| Sector | Tecnología |
| Industria | Biotechnology |
| Mercado | NASDAQ |
| Capitalización | 18.723.059 € |
| Beta | 0,33 |
| Sitio web | https://www.vistagen.com |
| CEO | Shawn K. Singh |
| Fecha de IPO | 21/06/2011 |
| País | US |
| Dirección | 343 Allerton Avenue, South San Francisco, CA, 94080 |
| Volumen | 369.899 |
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a rang...
VistaGen Therapeutics, Inc opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones